<DOC>
	<DOCNO>NCT01864265</DOCNO>
	<brief_summary>By use functional MRI investigator recently show TNFi elicit rapid change brain function link perception RA [ 5 ] . Functional MRI represent method allow detect tiny change neuronal activity measure alteration blood flow context neuronal activation . TNFi rapidly reverse widespread activation brain center involve pain thalamus somatosensoric cortex , well involve control , mood emotion limbic system . Moreover , small phase I study 10 patient RA show high brain activity detect functional MRI predict clinical response Certolizumab Pegol 1 month , suggest central nervous system activity may use tool predict response TNFi [ 8 ] . The rationale study test whether response TNFi predict use functional MRI .</brief_summary>
	<brief_title>Prediction Response Certolizumab Pegol Treatment Functional MRI Brain</brief_title>
	<detailed_description>Randomized double-blinded controlled multi-centre , study 12 week , follow 12 week single blind multicenter trial 156 patient RA inadequate response DMARD therapy . The study compose 3 arm 1:1:1 randomization baseline : High functional MRI/400mg Certolizumab Pegol week 0,2 4 follow Certolizumab Pegol 200mg every two week total 24 week ; low functional MRI/400mg Certolizumab Pegol week 0,2 4 follow Certolizumab Pegol 200mg every two week total 24 week possibility early escape week 12 . Patients respond sufficiently accord EULAR response criterion ( DAS28 reduction ≥ 1.2 ) Certolizumab-Pegol ( Treatment Arm A Arm B ) 12 week off-Study treat accord local guideline . Patients Placebo group EULAR response ≥ 1.2 reach remission ( DAS28 ≤ 2.6 ) also study treat accord local guideline follow clinical remission . Patients EULAR response ( DAS28 reduction ≥ 1.2 ) fulfil clinical remission criterion ( DAS28 ≤ 2.6 ) receive Certolizumab Pegol week 12,14 16 Certolizumab Pegol 400mg s.c. follow s.c.injection 200mg Certolizumab Pegol every two week till week 24 . In situation one group sufficient patient randomize , fMRI do screening , need analyze first ensure patient randomize randomization close group . A blinded person , involve either analysation fMRI treatment patient clinical assessment , responsible randomization list . If next number randomization list represent number close group , patient eligible study treat accord local guideline .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Understands voluntarily sign inform consent form Male female , age ≥ 18 year time consent Must able adhere study visit schedule protocol requirement Must satisfy 2010 ACR/EULAR classification criterion rheumatoid arthritis plus disease duration least 6 month . Must active RA DAS28 ≥3.2 Must RF and/or ACPA positive ≥ 3 swollen and/or tender joint hand At screen visit patient treat without alteration therapy least three month DMARDS ( i.e . Methotrexate ) without concomitant use steroid ) . Glucocorticoids treatment 10mg prednisolone per day allow study entry . . Individuals able understand follow study protocol able voluntarily sign informed consent Individuals willing follow study protocol sign inform consent Individuals claustrophobia , tattoos contain metal , magnetic endoprostheses , surgery bone time interval &lt; 3 month . Patients treat biological small molecule medication investigation treatment RA . Patients serious chronic infection within previous 3 month Opportunistic infection within 6 month screen Cancer within 5 year screen ( exception treat cure squamous basal cell carcinoma skin ) History severe congestive heart failure Current sign symptom severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal ( a.e.diverticulitis ) , endocrine , pulmonary , cardiac , neurologic cerebral disease Transplanted organ ( exception corneal transplantation do 3 month screen ) Evidence active tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>functional MRI</keyword>
	<keyword>Prediction Response</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>RF and/or ACPA positive</keyword>
</DOC>